-
St. Jude Medical (Minneapolis, Minnesota) reported receiving FDA approval and European CE marking, as well as the first implant of its Atlas Plus implantable cardioverter defibrillator (ICD), which it said is the highest-output (36 joules delivered/42 joules stored) rate-adaptive device on the market. High-energy outputs are particularly helpful for patients who have life-threatening high or rising defibrillation thresholds, the company said.
-
-
Inactivated trivalent influenza vaccine did not reduce the incidence of acute otitis media among children 6-24 months of age.
-
By determining whether 4 key risk factors are present, clinicians might be able to identify those patients with S aureus bacteremia who are at increased risk of serious, complicated infection.
-
Azithromycin administration to patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection was associated with a reduction in number of exacerbations, improvement in airflow, and weight gain.
-
Atazanavir (Reyetaz®), an azapeptide class of protease inhibitors, was approved by the US FDA for use in HIV infection on June 20, 2003. Atazanavir (ATV) has a unique pharmacokinetic profile allowing for once-daily dosing, which is optimized when taken with food.
-
-
-
The following summary of selected abstracts from 3 meetings will be published in multiple parts. The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) met in Chicago September 14-17, 2003. The Infectious Disease Society of America (IDSA) met in San Diego October 9-12, 2003. The American Society of Tropical Medicine and Hygiene meets in Philadelphia December 3-7, 2003.
-
Genetically engineered B lymphocytes were used for rapid detection and identification of pathogens, a methodology with potential use in diagnostics, biowarfare defense, and biomonitoring of food and water.
